{"entity":{"id":"idea-reg-hpapi-continuous-flow","kind":"idea","name":"Continuous-flow synthesis of ultra-potent ADC payloads to ease the capacity squeeze","aka":[],"tldr":"The poisons carried by antibody-drug conjugates are so toxic that only a few factories can make them, and they are booked years ahead. Making them in small continuous reactors would ease the bottleneck.","summary":"Capacity to make the toxins carried by ADCs, such as exatecan derivatives, maytansinoids and auristatins, is concentrated in a small number of contract manufacturers with multi-year lead times, and handling these toxins in batches, even in milligram quantities, requires costly containment. Continuous-flow chemistry in enclosed micro- or meso-reactors reduces the inventory of toxic intermediates at any moment, shrinks containment footprint and allows numbering-up rather than scale-up. The proposal is a pre-competitive programme to develop and regulator-qualify flow routes for the three most used payload classes and license them openly to manufacturers.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)","url":"https://doi.org/10.1001/jamaoncol.2018.0977"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":["trastuzumab-deruxtecan","enfortumab-vedotin"],"companies":[],"institutions":[],"pathways":[],"terms":["payload"],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy"],"keyPapers":["paper-hernandez-jama-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Qualified flow routes cut the cost of goods of payload-linker per gram by at least a third and reduce contract lead times for new ADC programmes from over 18 months to under nine.","rationale":"Continuous manufacturing is already accepted by FDA and EMA for several small molecules and is well suited to hazardous chemistry; the payload chemistries are known and the constraint is capital and containment, both of which flow reduces.","test":"Fund two academic-industrial groups to demonstrate GMP-grade flow synthesis of exatecan and MMAE at 100-gram scale, with regulator engagement on the control strategy, and publish cost and lead-time comparisons.","maturity":"preclinical-evidence","actor":"engineering","cost":"medium","horizonYears":3},"route":"/ideas/idea-reg-hpapi-continuous-flow/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"term":[{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"paper":[{"id":"paper-hernandez-jama-oncol","kind":"paper","name":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","route":"/key-papers/paper-hernandez-jama-oncol/"}]}}